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Abstract: The use of stem cells for reparative medicine was first proposed more than three 
decades ago. Hematopoietic stem cells from bone marrow, peripheral blood and human 
umbilical  cord  blood  (CB)  have  gained  major  use  for  treatment  of  hematological 
indications. CB, however, is also a source of cells capable of differentiating into various 
non-hematopoietic cell types, including neural cells. Several animal model reports have 
shown  that  CB  cells  may  be  used  for  treatment  of  neurological  injuries.  This  review 
summarizes the information available on the origin of CB-derived neuronal cells and the 
mechanisms proposed to explain their action. The potential use of stem/progenitor cells for 
treatment of ischemic brain injuries is discussed. Issues that remain to be resolved at the 
present stage of preclinical trials are addressed. 
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1. Introduction 
Ischemic brain and spinal cord injuries, as well as neurodegenerative diseases, represent poorly 
managed diseases  that are major targets  for pharmacological  intervention. Modern approaches  are 
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based on cell and gene therapy [1]. They include implantation/transplantation of neuronal cells or cells 
engineered with specific gene encodings for neuroprotective growth factors. For example, human fetal 
mesencephalic dopaminergic tissue and chromaffin cells when transplanted into damaged tissues of the 
central nervous system (CNS) were found to replace lost dopaminergic phenotype [2,3]. However, 
clearly there are ethical concerns and a limit to the supply of the tissues mentioned as well as recent 
concerns with side effects [3]. Alternative sources of tissue have been investigated, and stem cells are 
an attractive renewable tissue supply. Although not yet clinically available for central nervous system 
disorders,  stem  cell  technology  is  expected  to  evolve  into  one  of  the  most  powerful  tools  in  the 
biological management of complex central nervous system disorders, many of which currently have 
limited treatment modalities.  
Neural stem cells are multipotent precursors that both self-renew and give rise to neuronal and glial 
progenitors [4]. They are present in the developing [5] and also in the adult central nervous system of 
mammals, including humans [6,7]. Neural stem cells were isolated from embryonic, bone marrow and 
adult subsets of both human and murine origin, and in the last few years from human umbilical cord 
blood  (CB)  [8,9].  Some  sub-populations  isolated  from  CB  have  been  shown  to  differentiate  into 
neural-like  cells  and  when  administered  in  animal  models  of  brain  ischemia,  neurodegenerative 
diseases  and  spinal  cord  injuries  they  exhibited  therapeutic  effect  [8,9].  Recent  advances  in 
understanding the unique biology of CB will further expand indications for its use in different settings, 
including those beyond transplantation for hematopoietic-related illnesses, such as neurological-related 
diseases [10,11]. 
2. CB—An Attractive Potential Source for Brain Regeneration  
Considering its growing use for hematological reconstitution, its widespread availability and the 
potential use in non-hematopoietic related-diseases, CB is an attractive source for tissue regeneration 
[12,13]. With the annual global birth rate of over 100 million per year and the fast availability of 
cryopreserved units, CB is a large underutilized stem cell source with many innate advantages. For the 
treatment of brain injuries, the collection of stem cells from CB of a placental umbilical cord stump is 
simpler compared to the more complex collection from bone marrow or from embryonic human brain. 
Furthermore, a paramount advantage of CB stem cells over adult stem cells is that they possess a 
primitive ontogeny and have not been exposed to immunologic challenge. This rather naï ve immune 
system of CB cells may play a significant role in reduced rejection after their transplantation into a 
mismatched host [12]. Indeed, when comparing the records of recipients of CB from human leukocyte 
antigen (HLA)-matched siblings and recipients of HLA-matched bone marrow, a lower risk of acute 
graft-versus-host-disease (GVHD) and chronic GVHD among the CB transplant patients was found 
[12,14]. Another advantage of CB is the increasing number of public banks and the eligibility of its use 
for transplantations.  While research with  embryonic stem  cells  continues  to  generate considerable 
controversy, human umbilical stem cells provide an alternative cell source that has been more ethically 
acceptable  and  appears  to  have  widespread  public  support,  with  43  public  CB  banks  in  26  
countries [15].  
The  successful  transplantations  of  CB  as  an  alternative  to  bone  marrow  for  the  treatment  of 
hematopoietic-related diseases [12] provide important evidence that CB-related therapies are feasible 
and may be further suggested to non-hematopoietic applications, such as brain injuries. Currently, CB Int. J. Mol. Sci. 2010, 11                       
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is considered a second best choice after matched bone marrow. However, results of recent international 
studies indicate that in particular clinical settings, such as in children with leukemia, CB may become a 
frontline hematopoietic stem cell source for transplantation. With these advantages, however, the CB 
limited cell dose remains a main setback of CB transplantations, particularly in adult population. New 
strategies, such as transplantation with two cord blood units or using non-myeloablative conditioning, 
have  remarkably  expanded  the  availability  of  CB  transplants  in  adults  with  hematological 
malignancies [16]. Clinical trials with in vitro expanded CB-derived stem cells are under way [12].  
Considering its many advantages and since CB was found to contain a mixture of different types of 
stem  cells  in  numbers  not  seen  in  any  other  location,  including  embryonic-  like  stem  cells, 
hematopoietic  stem  cells,  endothelial  stem  cells,  epithelial  stem  cells,  mesenchymal  stem  cells, 
unrestricted somatic stem cells and neuronal stem cells [8,9], we believe it may become a frontline 
source of cells for therapy, including for the treatment of brain injuries.  
3. Neural Stem Cells from CB—An Unclear Origin  
During the last decade, numerous in vitro studies have demonstrated generation of neuronal cells 
from CB progenitors [8,9]. The experimental approaches to induce neural differentiation were based 
on supplementation of growth factors such as NGF [17] and interferon-gamma [18] as well as of 
chemical agents, such as retinoic acid [19–22], dimethylsulfoxide [23] and beta-mercaptoethanol [24]. 
The induction of neuronal phenotypes was characterized by the expression of typical neuronal markers 
specific to different stages of neural development and by functional proteins, including voltage- and 
ligand-gated  ionic  channels  [25].  For  instance,  McGuckin  et  al.  demonstrated  the  presence  of 
embryonic stem (ES)-like cells in CB, from which under expansion with thrombopoietin, flt-3, and  
c-kit ligand, slow-dividing adherent cell populations resulted with neuroglial progenitor morphology, 
upregulation  of  primitive  neuroglial  cell  markers,  and  expression  of  glial  fibrillary  acidic  protein 
(GFAP) [26]. Our group isolated a subpopulation of collagen-adherent cells from CB [17]. Under in 
vitro  treatment  with  neuronal  conditioning  medium,  NGF  and  interferon-gamma,  these  cells 
differentiated into a neuronal-like lineage, expressing neuronal (NeuN, neuron specific enolase-NSE, 
neurofilaments, microtubulin associated protein-MAP-2) and glial cells (GFAP) markers [18]. Chen et 
al. also characterized a subpopulation of adherent cells in the CB, expressing vimentin, nestin, and 
A2B5, antigens typically found in brain tissue, and the neurotrophic receptors, trk-A, trk-B and trk-C, 
suggesting  the  cells  ability  to  differentiate  by  growth  factors  towards  a  neural  phenotype  [27]. 
Buzanska et al. established a clonogenic non-immortalized CB neural stem cell line that could be 
maintained  in  culture  at  different  stages  of  neural  progenitor  development  with  trophic  factors, 
mitogens and neuromorphogens [28]. In parallel, Rogers et al. have isolated a population of CD45+ 
cells from CB with multipotential properties [29]. These stem cells were isolated by culture in a serum 
free,  growth  factor  supplemented  medium  and  were  capable  of  differentiating  into  bone,  muscle, 
neural, blood and endothelial cells after exposure to specialized differentiation media. The full range of 
neural differentiation ability of the cells was demonstrated by the achievement of positive phenotypic 
and functional  indicators  for dopaminergic neurons,  oligodendrocytes  and astrocytes  [29]. Finally, 
electrical  activity  of  CB-derived  CD34
-/CD45
-  differentiating  cells  was  recorded  using  whole-cell 
patch-clamp [25]. In these cells, gene and partially protein expression for voltage-dependent potassium 
and sodium channels and the neurotransmitter receptors acetylcholine (ACh), gamma-aminobutyric Int. J. Mol. Sci. 2010, 11                       
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acid (GABA), glutamate, glycine, 5-hydroxytryptamine (5-HT), and dopamine (DA) were identified 
and the cells further displayed an inward rectifying potassium current (Kir) and an outward rectifying 
potassium current (I(K+)). Kainic acid (KA), a non-N-methyl-D-asparate (NMDA) glutamate-receptor 
agonist, induced an inward current in some of the cells, while KA, glycine, DA, ACh, GABA, and  
5-HT partially blocked Kir through their respective receptors, indicating differentiation toward neuron-
like cells, with functional voltage- and ligand-gated channels identified in other neuronal systems [25]. 
In similarity to the diversity in the reported differentiating methods, the cell type or subpopulation 
of cells, which is the source of neurons and glia from CB, also remains undefined. Most studies used 
heterogeneous or poorly characterized populations of CB cells. Some were defined according to their 
classification  as  hematopoietic  and  non-hematopoietic  stem  cells  and  there  were  no  standardized 
criteria  for  determination  of  their  origin.  To  date  it  is  common  to  isolate  and  characterize 
hematopoietic and non-hematopoietic stem cells by the expression or lack of expression of CD34, 
CD45 and/or CD133 antigens, respectively.  
Subpopulations of CB isolated according to the expression of hematopoietic stem cells markers 
such as CD34
+ [30], CD133
+ [21,31] or CD45
+ [29] were induced in vitro to differentiate towards 
neuronal-like phenotype. Subsequently, CD34
- CD45
- non-hematopoietic stem cells [20,22,25], and 
MSC [23,32] and unrestricted somatic stem cells (USSCs) [33,34] were identified as origins of the 
neuronal-like cells. Classically, MSC are defined as being able to adhere to plastic, expressing CD29, 
CD73,  CD44,  CD90,  CD105  antigens,  and  not  expressing  the  hematopoietic  cell  markers  CD34, 
CD45, and MHC class II antigen  [35], although none of these markers appears to be exclusively 
expressed on MSC [36]. The MSC origin was determined by the expression of various MSC markers 
and  was  further  supported  by  showing  that  some  CB-derived  progenitors  adhere  to  plastic  and  
poly-l-lysine [19,27,37,38].  We isolated  a subpopulation  of cells,  capable of differentiating into a 
neuronal phenotype using their collagen adherent properties and positive expression of alpha1 and 
alpha2 collagen-receptors [17]. The microarray gene expression analysis of these cells indicates that 
the cells are negative for the hematopoietic markers CD34, CD49c, CD49d, CD62e, CD62p, CD106, 
CD117, CD133, CD235a, HLA-DRB4, HLA-DRB4 and HAS1, and positive for the mesenchymal 
markers CD13, CD29, CD44, CD49a/b, CD49e, CD73, CD105 and vimentin [18], supporting their 
USSCs/MSC origin.  
Altogether, the uncertainty in the precise origin of the CB-cells differentiating into a neuronal-like 
phenotype (hematopoietic or non-hematopoietic progenitors), is reflecting on our inability to determine 
whether a primitive multipotent stem cell resides in CB or whether a transdifferentiation process [39] 
is  responsible  for  neuronal  differentiation  from  hematopoietic  lineage.  The  transdifferentiation 
hypothesis, proposed during the last decade, is challenging the concept that a cell committed to a 
specific phenotypic fate, by virtue of residence in a mature organ, cannot change its destiny. However, 
one  must  be  cautious  when  interpreting  transdifferentiation  whereas  the  molecular  mechanisms 
responsible for stem cell plasticity are not completely understood. It is also possible that the stem cells 
found in adult tissues are true multipotent stem cells that arrive in the adult tissue early in development 
(or  perhaps  migrate  to  the  organ  later  in  development),  but  retain  “stemness”  (self-renewal, 
multipotency) in the adult tissue throughout life [39].  
In this view, the specific identification of the CB-derived cells with neural differentiation abilities, 
as hematopoietic or non-hematopoietic source may be crucial for their further definition as neuronal or Int. J. Mol. Sci. 2010, 11                       
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non-neuronal originated stem cells. However, even if originated from a non-neuronal stem cell, once 
have  the  ability  to  differentiate  into  a  neuronal  phenotype  and  provide  neuroprotection  against 
neurological deficits, CB cell populations are of high clinical relevance.  
4. Therapeutic Effect by CB-Derived Cells on Ischemic Brain Injury  
Cerebral ischemia induces death of all neural cell types within the region affected by the loss of 
blood flow. On the other hand, neurodegenerative diseases, such as Amyotrophic lateral sclerosis, 
Alzheimer’s,  Huntington’s  and  Parkinson’s  diseases  involve  degeneration  of  defined  neuronal 
phenotypes in the CNS [8]. In both cases, most therapies for these diseases are palliative rather than 
restorative and the quality of life of the affected individuals is greatly impaired. Stem cells may confer 
neuroprotection which holds the promise of resulting in the replacement or regeneration of damaged 
neurological tissues. "Neuroprotection" was coined to describe interventions protecting the brain from 
pathological  damage.  The  neuroprotective  drug/approach  aims  at  preventing  the  death  of  cells  by 
inhibiting insult-activated pathological step(s) and/or induction of biochemical pathways that induce 
survival.  This  drug/approach  may  also  confer  neuroprotection  by  induction  of  neurogenesis,  as 
observed by proliferation and migration of endogenous stem cells to the site of brain injury, or upon 
exogenous transplantation [40]. It was shown that in stroke, neuroprotection involves the inhibition of 
pathological events leading to calcium influx, activation of free radical reactions and cell death [41]. It 
is  important  to  note,  however,  that  the  cell  therapy  strategy  may  differ  according  to  the 
pathophysiology of the disease. Whereas in chronic neurodegenerative diseases a defined neuronal 
pathway is degenerated, in acute ischemic brain injuries the damage occurs within various regions of 
the brain. A rational treatment for ischemic brain injuries will therefore include the support of the 
injured  cell  survival  and  an  induction  of  endogenous  neurogenesis,  while  for  the  treatment  of 
neurodegenerative diseases a cell replacement approach may be more effective. 
A major challenge is to develop a neuroprotective therapy for ischemic brain patients that can be 
applied in the early stages of the insult to slow, stop, or reverse the progression of the disease. Over the 
last two decades, more than 500 drugs demonstrated neuroprotective properties in pre-clinical and 
clinical setups, however, none have reached the stage of an “approved” therapy [42,43]. Innovative 
approaches,  such as neuroprotection by stem  cells,  raise  hope in  the clinic.  Indeed,  recent animal 
studies and preclinical trials have provided evidence that cell-based, regenerative therapies can lead to 
functional recovery of brain ischemia patients. Stem cells can differentiate into neuronal or neuron-like 
cells that may replace lost neurons or provide trophic support to tissue at risk in the infarcted area of the 
brain  and  help  to  promote  survival  and neuroprotection  [44].  However,  stem  cell–based  therapy  is 
problematic because aborted human fetuses from which human neuronal stem cells are isolated are 
scarce  and  raise  complicated  ethical  issues.  High-quality,  neuronal  progenitor  cells  from  CB,  if 
available in sufficient quantity, might provide a viable alternative. 
The ability of CB and derived cell populations to award protection against neurological deficits was 
shown  in  vivo in  models  of  ischemic brain injuries.  Using a transient  (two-hour)  MCAO (medial 
carotid artery occlusion) model of stroke, Chen et al. were the first to demonstrate that upon CB 
intravenous administration, many of the physical and behavioral deficits were ameliorated [45]. A 
significant improvement in functional outcome
  on motor and modified neurological severity score 
(mNSS) tests was found in animals given CB cells at 1 day after stroke. At 14 and 35 days after Int. J. Mol. Sci. 2010, 11                       
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transplantation,
 intravenously injected CB cells were found in the brain, and significantly
 more CB 
cells  were  found  in  the  ipsilateral  hemisphere  than  in
  the  contralateral  hemisphere.  Many  cells 
migrated into the boundary
 zone of ischemic brain. CB cells survive, and some express cell type–
specific neuronal markers NeuN (2%) and MAP-2 (3%), astrocye marker GFAP (6%) and endothelial 
cell marker FVIII (8%). In vitro, using a brain tissue extract assay, a significant CB cells migration 
activity was shown in the presence of
 ischemic cerebral tissue harvested at 24 hours after MCAO 
compared  with  normal  nonischemic  brain  tissue  [45].  Furthermore,  using  ischemic  brain  extracts, 
Newman  et  al.  suggested  that  the  migration  of  CB-cells  into  the  ischemic  area  is  triggered  by 
cytokines  and  chemokines  released  in  the  ischemic  tissue  [46].  These  observations  were  further 
supported  by  other  groups,  monitoring  the  dependence  of  the  beneficial  effects  on  the  CB  cell 
dose [47], mode of cell implantation [48] and the timing of transplantation after injury [49]. Using a 
permanent MCAO, Vendrame et al. found an inverse relationship between CB cells dose and damaged 
infarct volume [47]. Furthermore, at four weeks after intravenous infusion, there was a significant 
recovery in behavioral performance only when 10
6 or more CB cells were delivered [47]. Intravenous 
delivery was suggested to be more effective than striatal delivery in producing long-term (two-months 
after implantation) functional benefits to the stroked animals [48]. The therapeutic efficacy of the 
treatment  was  demonstrated  even  when  cells  were  administrated  48  hours  after  the  injury  [49]. 
Successful treatment at this time point should offer encouragement to clinicians that a therapy with a 
broader window of efficacy may be available to treat ischemic stroke.  
In  vivo  animal  studies  succeeded  in  using  CB  also  for  the  treatment  of  heatstroke.  Under  an 
exposure  to  an  ambient  temperature  of  43  degrees  C,  rats  transplanted  with  intravenous  or 
intracerebroventricular CB cells showed a significant improvement in their survival as composed to 
the non-transplanted group (61–148 min. vs. 21–23 min., respectively) [50]. The circulatory shock, 
intracranial hypertension, cerebral hypoperfusion and hypoxia, increment of cerebral ischemia, and 
damage markers during heat stroke were all significantly attenuated by the delivery of CB-cells but not 
peripheral  blood  mononuclear  cells.  Furthermore,  treatment  with  CB-derived  CD34+  cells 
significantly improved survival time (63–291 min) while causing attenuation of hypotension, hepatic 
and  renal  failure,  hypercoagulable  state,  activated  inflammation,  and  cerebral  ischemia  and  injury 
heatstroke reactions. In addition, the levels of IL-10 in plasma and glial cell line-derived neurotrophic 
factors in brain were all significantly increased after CB-CD34+ cell therapy during heatstroke [51]. 
This data indicate that CB, but not peripheral blood, cell therapy may resuscitate persons who had a 
heatstroke by reducing multiorgan dysfunction or failure. 
Traumatic brain injury is also a potential target for treatment using CB cells as was first indicated 
by Lu et al. [52]. They documented migration of intravenous transplanted cells into the parenchyma of 
brain lesion and a decrease in neurological damage in a rat model. The cells expressed the neuronal 
markers, NeuN and MAP-2, and the astrocytic marker, GFAP. Some CB cells integrated into the 
vascular walls within the boundary zone of the injured area [52].  
Treatment with CB cells was also proposed for other brain damages, such as hypoxic-ischemic 
damage around birth. Using brain damaged neonatal rats, Meier et al. observed both incorporation of 
CB mononuclear  cells  in the lesioned brain  area and an  alleviation  of  the neurological effects  of 
cerebral palsy as assessed by footprint and walking pattern analysis [53]. This was also observed under 
intracerebral  transplantation  of  MSCs,  which  were  found  to  differentiate  into  astrocytes,  but  not Int. J. Mol. Sci. 2010, 11                       
 
3519 
neurons [54]. Furthermore, a pilot study is in progress at Duke University to test the feasibility (of 
collection, preparation and infusion) using autologous CB on a baby born with signs of brain injury 
during the first 14 days after birth (http://www.clinicaltrials.gov/ct2/show/NCT00593242?order = 1). 
5. CB-Induced Therapeutic Effect on Ischemic Brain Injury—Routes for Mediating Mechanisms  
Although  functional  improvement  and  reductions  in  lesion  volume  were  observed  in  ischemic 
rodents treated with CB cells, cells expressing the human nuclei marker within the brain were rather 
scant, suggesting that the restorative effects of CB may be mediated by mechanisms other than cell 
replacement [55]. Some of the mechanisms proposed for these studies involves reduced inflammation 
[49,56,57], nerve fiber reorganization by trophic actions [55], increased cell survival and enhanced 
angiogenesis [58,59]. Evidences for reduced inflammation included the suppression of lymphocytes 
[57], granulocyte and monocyte [49] infiltration and the lack of astrocytic and microglial activation in 
the parenchyma [49]. They also included the rescue of spleen weight and splenic CD8+ T-cell counts 
[56] and an increase in the production of IL-10 while decreasing IFN-gamma [56]. To determine 
whether CB-cells could exert trophic effects on the host brain, Xiao et al. directly transplanted the cells 
into the brain parenchyma after ischemic brain injury and showed an increased sprouting of nerve 
fibers from the non damaged hemisphere into the ischemically damaged side of the brain [55]. Their 
results  suggest  that  restorative  effects  observed  with  CB-cells  treatment  following  ischemic  brain 
injury  may  be  mediated  by  trophic  actions  that  result  in  the  reorganization  of  host  nerve  fiber 
connections within the injured brain. CB-MCSs [58] and CB-CD34‏  positive cells [59] were suggested 
to promote either directly or indirectly an environment conducive to neovascularization of ischemic 
brain  so  that  neuronal  regeneration  can  proceed.  Ding  et  al.  showed  that  transplanted  CB-MSCs 
migrated  towards  the  ischemic  boundary  zone,  were  able  to  differentiate  into  glial,  neuronal, 
doublecortin+, CXCR4+, and vascular endothelial cells and that CB-cells transplantation promoted the 
formation of new blood vessels [58]. These results suggest a potential enhanced neuroplasticity as well 
as an increase local cortical blood flow in the ischemic hemisphere, supporting brain plasticity and 
recovery. Furthermore, in a canine thromboembolic brain ischemia model, transplanted CB-MSCs had 
differentiated into neurons and astrocytes and were observed in and around endothelial cells that were 
positive for von Willebrand factor (vWF) [60]. These cells expressed neuroprotective factors, such as 
brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF), at  four 
weeks after the transplantation, in correlation to reduced infarct volume and earlier recovery from the 
neurological deficit [60].  
We and others have widely explored these mechanisms in vitro [61–63]. CB-derived progenitors 
were  shown  to  confer  neuroprotection  in  models  of  cerebral  ischemia  using  oxygen  glucose 
deprivation  (OGD)  insulted  adrenal  medulla  neurons  [61],  primary  rat  cortical  neuronal  cultures 
exposed  to  hypoxia  and  hippocampal  slice  cultures  exposed  to  OGD  [57,62],  as  well  as  on 
differentiated neuroblastoma SH-SY5Y cells exposed to hypoxia [63]. This protection is rationalized 
by a mechanism involving the release of antioxidants, the decrease in numbers of free radicals in the 
injured neuron and the accumulation of growth factors in the media. This includes the release of the 
nerve growth factor (NGF), VEGF and basic fibroblast growth factor (bFGF) and the modulations of 
neurotrophic and angiogenic factors gene expression [61]. As these CB cells selectively home into the 
lesioned brain areas [45,46,52,53,58], the release of neurotrophic and angiogenic factors [64,65] and/or Int. J. Mol. Sci. 2010, 11                       
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antioxidants in vivo, as shown in vitro, would be highly specific and locally limited to the damaged 
brain area, supporting a ”bystander” neuroprotective strategy [66]. 
A “bystander” protection of the ischemic neuron refers to an effect mediated by soluble growth 
factors  and not  by  neurogenesis (proliferation and differentiation of neuronal  stem  cells  replacing 
neuronal network). The concept of bystander cell therapy is expected to replace or complement the 
common  method  of  providing  neurotrophins  to  the  injured  brain  [67].  Clinical  trials  testing  the 
therapeutic  properties  of  various  neurotrophic  factors  have  been  rather  disappointing  [68,69]. 
Neurotrophins are relatively large proteins, that do not penetrate the blood-brain barrier [70] and the 
poor outcome of clinical trials can be partially attributed to the inability of neurotrophins to effectively 
reach the brain. An alternative to the administration of neurotrophins or their agonists is to use small 
blood-brain-barrier-penetrating molecules, which stimulate the production and release of neurotrophins 
in the brain [67] or, as presently suggested, to implant/transplant neuronal stem cells with the ability to 
secrete neurotrophins in the insulted area. 
6. Therapeutic Effect of CB-Derived Cells on Ischemic Brain Injury—A Glance to the Future 
CB-cells hold tremendous potential for the treatment of neurological diseases and are already used 
in the clinic for the treatment of hematological-related diseases. However, in order to be ethically 
accepted for the therapy of neurological disorders many issues should be resolved with pre-clinical 
studies before proceeding with clinical treatment.  
An  important  question  is  which  of  the  various  CB  population(s)  is  the  one  that  best  induces 
neuroprotection. This question must be separately addressed for each neurological disease, since the 
leading pathophysiologal processes are different in chronic neurodegenerative diseases from those in 
acute brain ischemia. The answer will determine which cell-population(s) to use for treatment and the 
strategy for cell therapy. Whereas for the treatment of ischemic brain injuries neuroprotection by a 
“bystander” effect may be more suitable for the coincidence nature of these diseases, the treatment of 
degenerated  defined  neuronal  phenotype  in  neurodegenerative  diseases  may  involve  both  cell 
replacement and neuroprotection strategies. Furthermore, even though transplantation of whole CB 
may be simpler, it contains several types of cells and may either induce a stronger immune response 
and/or may be less effective. The risk of graft versus host disease (GvHD) in CB transplantations for 
neurological applications has to be also quantified. In spite of the naï ve nature of the immune system 
of  a  newborn  and  reports  of  lower  incidence  of  GvHD  for  hematological  applications  [71],  this 
complication is  still viable  and need to  be addressed.  Other issues  concerning the use of CB  for 
hematological-related  diseases  should  also  be  considered  regarding  its  potential  use  as  a 
neuroprotectant in ischemic brain injuries. One prime concern is the limited cell dose remains a main 
setback of CB transplantations, particularly in the adult population. Currently, a single unit of CB only 
provides cells in sufficient quantity to treat successfully neonatal or small-stature pediatric patients 
with hematological malignancies and other conditions requiring lymphohematopoietic reconstitution. 
Whether a single CB unit will be sufficient for therapy of ischemic brain is to be determined. Given 
ischemic brain injuries generally occurs in adult patient, most probably their treatment with CB will 
include new strategies such as transplantation with two cord blood units or using non-myeloablative 
conditioning,  which  have  remarkably  expanded  the  availability  of  CB  transplants  in  adults  with 
hematological malignancies [12,16]. In vitro expansion of CB-derived cells before transplantation is Int. J. Mol. Sci. 2010, 11                       
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also  a  potential possibility.  Finally, considering the  currently un-uniformed protocols  for CB-cells 
isolation and transplantation in ischemic brain injuries animal models, it is difficult to evaluate if there 
is  a  significant  impact  of  biological  differences  intrinsic  to  individual  units  of  CB  on  the 
reproducibility of results observed. This issue is to be addressed in a coherent research in order to 
predict the expectations in human subjects.  
A better understanding of the mechanism and identification of specific cell populations will provide 
stronger  rationale  for  considering  initiation  of  clinical  investigations  in  humans.  One  of  the 
mechanisms to be solved is the identity of the released factors after transplantation.  For example, 
cytokines and chemokines enhance the expression of adhesion molecules on cerebral endothelial cells, 
resulting  in  further  impairing  the  cerebral  blood  flow.  Therefore,  even  if  CB  cells  cannot  induce 
neurogenesis in an injured brain, their transplantation may still result with neuroprotection due to the 
secretion  of  factors  which  impair  the  cerebral  blood  flow  and  survival  of  damaged  brain  area. 
Furthermore, to date there is mounting evidence that inflammation plays an important role in cerebral 
ischemia. Experimentally and clinically, response to ischemic injury is associated with an acute and 
prolonged inflammatory process characterized by the activation of resident glial cells, production of 
inflammatory cytokines as well as leukocyte and monocyte infiltration in the brain [72]. These are all 
events that may contribute to ischemic brain injury and affect recovery and plasticity of the brain [72]. 
However, whether the post-ischemic inflammatory response is deleterious or beneficial to the recovery 
of the brain, is presently a matter of debate and controversies  [73]. Several investigators found a 
suppression  of  certain  compartments  of  inflammation  process  in  stroke  animals  after  CB-cells 
transplantation  [49,56,57].  However,  CB-neuronal-like  cells  originate  in  a  hematologic  tissue  and 
since  their  hematopoietic  or  non-hematopoietic  nature  is  yet  to  be  determined,  an  increased 
inflammatory effect upon their transplantation is also a realistic possibility and therefore might either 
be beneficial or contribute to the evolution of tissue damage.  
Another main issue relates to the therapeutic time window for cell transplantation. To date, the 
Food  and  Drug  Administration  (FDA)-approved  drug  treatment  for  acute  ischemic  stroke  is  the 
anticoagulant thrombolytic tissue-plasminogen activator (t-PA), which must be administered within 
the first 3–4.5 h after the onset of acute ischemia [74]. Unfortunately, many of the stroke and brain 
trauma victims do not reach a medical facility within this narrow time window. In early reports, using 
bone marrow stem cells, a significant reduction in the core of the ischemic lesion was achieved at early 
intervention-,  ranging  from  3–12  h  after  stroke  onset  [75,76].  Later  reports  of  intracerebral, 
intravenous  or  intra-arterial  administration  of  bone  marrow  stem  cells,  starting  from  24  h  after 
transient  MCAO,  showed  improved  functional  outcome  in  a  similar  experimental  ischemic  stroke 
model. Even delayed treatment seven days and even one month after the stroke onset was reported to 
increase brain plasticity and to improve long-term functional outcome [77,78]. Similarly, significant 
improvements were observed in the behavioral defects of rats that received CB cells 24–72 h after 
MCAO  [45–49]  and  of  traumatic  brain  injury  [52].  The  time  window  for  effective  treatment  to 
enhance recovery from brain ischemia was found to be longer than that for acute neuroprotective 
stroke treatments: perhaps days or weeks, rather than minutes or hours after the ischemic onset [79].  Int. J. Mol. Sci. 2010, 11                       
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7. Conclusions 
CB cells have been in routine clinical practice for the past 20 years for hematological applications. 
The development of new therapeutic protocols in regenerative medicine requires the use of stem cells 
and CB is an important and readily available source of cells for these applications. CB-derived cells 
offer multiple advantages over adult stem cells and ES cells, including their immaturity, which may 
play a significant role in the rejection of generated tissue when transplanted into a mismatched host, 
their simple collection and their ethically acceptable for transplantations in humans.  
During the last decade, a growing body of evidence suggests that CB contains cells capable of 
differentiating into neural phenotypes, including neurons, astroglia and oligodendroglia. A substantial 
diversity  is  currently  reported  regarding  the  identity  of  these  cells  as  hematopoietic  or  non-
hematopoietic  stem  cells.  Furthermore,  cell  differentiation  towards  a  neural  phenotype  involves 
various protocols and the multipotency properties of the isolated cells are not clear. Regarding the lack 
of defined handling, these CB derived-cell populations are now under investigation to determine their 
possible application for treatment of neurological diseases [80]. Animal models have shown that CB-
cells  improve  recovery  in  neurodegenerative  diseases  such  as  amyotrophic  lateral  sclerosis, 
Parkinson’s  diseases  and  Alzheimer’s  disease  [8,9].  CB-cells  were  also  widely  shown  to  enhance 
recovery in animal after ischemic brain injuries such as stroke, heatstroke, traumatic brain injury and 
hypoxic-ischemic  damage  around  birth.  Upon  CB-cells  transplantation  in  ischemic  brain  damaged 
animals, these cells migrated to the injured brain area and some differentiated into neuronal, astroglial 
and  oligodendroglial  phenotypes.  In  these  transplanted  animals,  the  damaged  infarct  area  was 
decreased  in  a  reverse  correlation  to  the  transplanted  CB-cells  amount,  while  a  significant 
improvement  in  functional  outcome
  in  neurological  deficits  was  observed.  Both  intravenous  and 
striatal  delivery  were  suggested  to  be  effective  in  producing  long-term  functional  benefits  to  the 
ischemic brain injury animals and the therapeutic efficacy of the treatment was demonstrated even 
when cells were administrated 48 hr after the injury. Several mechanisms of action were suggested 
including reduction in inflammatory response reorganization of nerve fiber by trophic actions, increase 
in  damaged  cell  survival  and  enhancement  of  angiogenesis.  But  more  is  hidden  than  clear  and 
comprehensive investigation of the therapeutic properties is needed to provide stronger rationale for 
considering  initiation  of  clinical  investigations  in  humans.  This  will  include  determination  of  the 
identity of the cells active in neurorecovery and the cell populations of their origin, the mechanisms of 
therapeutic effects, the rout of cell administration, the time window for intervention and others. 
Ischemic brain injuries are known for the short time during which current available therapeutic 
activity is possible. However, considering the encouraging results using CB derived stem cells, their 
administration beyond the hyperacute phase of ischemia may amplify the intrinsic properties of the 
brain regarding neuroplasticity and subsequent neurological recovery. Therefore, although still in the 
pre-clinical stage of research, treatment by CB cells, which may extend the therapeutic window and 
provides significant improvements in neurological deficits, holds a tremendous potential for therapy 
and may create an opportunity to treat most, if not all, ischemic brain patients.  
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